Groundbreaking research cooperation: The Medi-Globe Group and the IHU in Strasbourg are developing the world's first AI software for detecting pancreatic diseases

 ACHENMÜHLE, Germany-Saturday 30 April 2022 [ AETOS Wire ]

(BUSINESS WIRE) -- The Medi-Globe Group has entered into a groundbreaking research cooperation with the French Institut Hospitalo-Universitaire (IHU) in Strasbourg. The goal of the collaboration is the world's first AI software for detecting diseases of the pancreas in endoscopic ultrasound examinations. As industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies.

Medi-Globe Group CEO Martin Lehner: "Together with the researchers at the IHU, we will develop the world's first software for the diagnosis of diseases of the pancreas to market maturity. The key technology here is artificial intelligence.”

“We are delighted to announce this special partnership with Medi-Globe Group. This collaboration is an important step in realizing our goal of being a technology leader in the application of artificial intelligence in the field of early detection of pancreatic diseases. Our vision has been to provide technologies that help physicians achieve the best outcome for their patients,” explains Benoit Gallix, CEO of IHU Strasbourg.

Important milestone in the diagnosis of pancreatic cancer in sight

Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose for physicians. Early detection is crucial for the patient's chance of survival. Today in Europe more than 90 percent of patients with pancreatic cancer die.

"In the future, with the support of artificial intelligence, we will be able to make the experience of the world's leading gastroenterologists available to all physicians. Our successful cooperation with the IHU has the potential to revolutionize the diagnosis of pancreatic diseases", says Marc Jablonowski, Chief Technology & Innovation Officer (CTIO) of the Medi-Globe Group.

About Medi-Globe Group

The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Bavaria. Around 670 employees work for the Medi-Globe Group in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220429005471/en/

Contacts

press@medi-globe.de

braun communications

Stefanie Braun

+49 171 2 888 214

sb@brauncommunications.de

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

ST. GALLEN, Switzerland & STAMFORD, Conn. -Thursday 28 April 2022 [ AETOS Wire ]

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients

First launches in Europe expected in H2 2022

(BUSINESS WIRE)-- Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005801/en/

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients. The marketing authorization, which approves Kapruvia® for use in all member states of the European Union plus Iceland, Liechtenstein and Norway, follows the U.S. Food and Drug Administration (FDA) approval of KORSUVA™ (difelikefalin) injection in August 2021 for the same indication. Kapruvia® will be the first therapy available in Europe for the treatment of CKD-associated pruritus in hemodialysis patients.

“We are very excited about the European Commission’s approval of Kapruvia®, marking an important milestone on our journey to advance and fundamentally change the treatment paradigm for people living with the severe burden of pruritus associated with chronic kidney disease,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “We look forward to bringing this first-in-class therapy to patients in Europe, with launch in first markets expected in the second half of 2022.”

“The European Commission’s approval of Kapruvia® provides a much-needed therapy to hemodialysis patients in Europe who suffer from pruritus,” said Dr. Joana Goncalves, Chief Medical Officer of Cara Therapeutics. “We are excited to bring an innovative drug to physicians to help change the way pruritus is managed. We continue to work with our commercial partner VFMCRP, to fill a significant unmet medical need among CKD patients with pruritus in both the U.S. and Europe.”

The approval in Europe is based on pivotal clinical data from two phase-III trials, KALM-1 and KALM-2, as well as supportive data from an additional 32 clinical studies. These studies showed that treatment with Kapruvia® resulted in clinically meaningful improvements in pruritus severity and in pruritus-related quality of life components and was found to be generally well tolerated in patients with moderate-to-severe CKD-associated pruritus.

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com

For more information, please visit viforpharma.com.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of oral difelikefalin are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

About Chronic Kidney Disease-associated Pruritus

CKD-associated pruritus is an intractable systemic itch condition that occurs with high frequency and intensity in patients with chronic kidney disease undergoing dialysis. Pruritus has also been reported in patients with stage III-V CKD who are not on dialysis. The majority of dialysis patients (approximately 60 to 70%) report pruritus, with 30 to 40% reporting moderate or severe pruritus.1,2,3 Data from the ITCH National Registry Study showed that among those with pruritus, approximately 59%4 experienced symptoms daily or nearly daily for more than a year.

Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years, with currently employed antipruritic treatments, such as antihistamines and corticosteroids, unable to provide consistent, adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression.4 CKD-associated pruritus is also an independent predictor of mortality and the risk for hospitalization among hemodialysis patients.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the potential timeline for the launch of difelikefalin solution for injection in Europe and the potential of difelikefalin solution for injection to be a therapeutic option for CKD-aP in dialysis dependent patients. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara's filings with the Securities and Exchange Commission, including the "Risk Factors" section of Cara's Annual Report on Form 10-K for the year ended 31 December 2021 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Cara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

References:

1 Pisoni RL, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2006; 21:3495-3505.

2 Ramakrishnan K, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. International Journal of Nephrology and Renovascular Disease. 2014; 7: 1-12.

3 Sukul et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med. 2020 Nov 21;3(1):42-53.

4 Mathur VS, et al. A longitudinal study of Uremic Pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1410-1419.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005801/en/

Contacts

Nathalie Ponnier

Global Head Corporate Communications

+41 79 957 96 73

media@viforpharma.com

Cara Therapeutics contacts:

Media Contact

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

Investor Contact

Iris Francesconi, PhD

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

Schlumberger Expands Global AI Innovation Network with Opening of Artificial Intelligence Center in Europe

 

Expanding the Benefits of Enterprise-Scale AI: Agile, Collaborative Development to Extract Maximum Value from Data

(BUSINESS WIRE) -- Schlumberger today announced it has expanded its global INNOVATION FACTORI network with the inauguration of a new center in Oslo, Norway.

“At INNOVATION FACTORI, customer teams will benefit from an agile, collaborative development approach with our domain and data science experts to address their strategic demands, such as drilling automation, digital twins for production optimization, and carbon capture and storage modeling,” said Rajeev Sonthalia, president, Digital & Integration, Schlumberger. “Through INNOVATION FACTORI, customers can turn promising concepts into fully deployed digital solutions that extract maximum value from data to drive a major leap in business performance and, in turn, sustainability.”

Schlumberger customers will gain access to a powerful machine learning platform with market leading AI capabilities. Through its partnership with Dataiku, a world leader in “Every Day AI,” Schlumberger will empower its customers to leverage a single, centralized platform to design, deploy, govern, and manage AI and analytics applications.

Schlumberger’s INNOVATION FACTORI network expansion comes after its successful inauguration of two AI centers in the Americas, one in Rio, Brazil, and a recently opened AI center in Houston, Texas. These centers compliment the global network of experts in Abu Dhabi, Beijing and Kuala Lumpur.

About Schlumberger

Schlumberger (SLB: NYSE) is a technology company that partners with customers to access energy. Our people, representing over 160 nationalities, are providing leading digital solutions and deploying innovative technologies to enable performance and sustainability for the global energy industry. With expertise in more than 120 countries, Schlumberger collaborates to create technology that unlocks access to energy for the benefit of all.

Find out more at www.slb.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws—that is, any statements that are not historical facts. Such statements often contain words such as “expect,” “may,” “can,” “believe,” “plan,” “estimate,” “intend,” “anticipate,” “should,” “could,” “will,” “likely,” “goal,” “objective,” “aspire,” “aim,” “potential,” “projected” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, digital technologies and partnerships. These statements are subject to risks and uncertainties, including, but not limited to, the inability to recognize intended benefits from digital strategies, initiatives or partnerships; and other risks and uncertainties detailed in Schlumberger’s most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of any such development changes), or should underlying assumptions prove incorrect, actual results or outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, Schlumberger disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005452/en/

Contacts

Giles Powell – Director of Corporate Communication, Schlumberger Limited

Tel: +1 (713) 375-3494

communication@slb.com

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

 LONDON-Friday 29 April 2022 [ AETOS Wire ]

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Siggi Olafsson, Hikma’s CEO, said:

“Hikma continues to make strategic progress, positioning the business for future growth through new product launches, continued investment in R&D, and new strategic partnerships and acquisitions, which are all driving our ability to put better health within reach, every day.

Our acquisition of Custopharm, which closed last week, enhances our R&D capabilities and pipeline while further expanding our portfolio of differentiated injectable medicines.  More broadly across the Group, we are seeing the benefits of our large and diverse portfolio which is helping us to offset increased competition in the Generics business, and underpins our confidence for continued growth this year.”

Injectables

Our global Injectables business is performing well.  In the US, Hikma is a top-two supplier of generic injectable medicines by volume[1] with a broad portfolio of close to 130 medicines. The return of elective surgeries continues and our diverse portfolio provides us with the flexibility to respond to the specific needs of our customers and address shortage issues. In Europe, we are seeing a good performance from our own products which is partially offsetting the anticipated reduction in contract manufacturing.  In MENA, we are seeing good demand across our markets, with performance in line with expectations.

Our Injectables business continues to make good strategic progress. In the US, we are on track with new launches and are pleased to add Custopharm’s 13 approved products to our extensive US portfolio.  In MENA, we have enhanced our biosimilar offering through our licencing agreement with Celltrion for Remsima®SC, the first subcutaneous formulation of infliximab.

We are updating our guidance to include a contribution from Custopharm. We now expect full year global Injectables revenue to grow in the mid to high-single digits, compared with our previous guidance of low to mid-single digits. We expect the core operating margin to be in the range of 36% to 37%, up from 35% to 37%.

Generics

In our Generics business, the year has started slowly, reflecting increased competition and the challenging pricing environment. These headwinds are being partially offset by opportunities we are generating through our strong customer relationships, broad portfolio, and flexible local operations.

We continue to expect full-year Generics revenue growth in the range 8% to 10% and core operating margin in the range of 24% to 25%, assuming a mid-year launch of sodium oxybate.  We expect Generics revenue will be weighted towards the second half of the year.

Branded

Our Branded business is performing well, as we maintain our focus on key therapeutic areas and chronic medications.  Our tier-one markets, Algeria and Egypt are performing strongly on a constant currency basis. Saudi Arabia has had a positive start to the year in the retail business, while the timing of government tenders will result in an overall weighting to the second half of the year. 

We continue to expect full-year 2022 Branded revenue to be in line with 2021. Excluding the $31 million impacts from hyperinflation in 2021, we expect Branded revenue to grow in the mid-single digits.

Final dividend and buyback

At our Annual General Meeting on 25 April 2022, our 2021 final dividend of 36 cents per share was approved and has been paid to shareholders. The final dividend brings the total dividend for the full year of 2021 to 54 cents per share, an increase of 8% in 2020.

We have been executing our share buyback programme, as announced on 25 February. This reflects the Group’s strong cash generation, balance sheet strength, and the Board’s confidence in the future growth prospects of the business. To date, we have completed an initial tranche of $150 million and are currently progressing with the second tranche of $75 million.

Following the acquisition of Custopharm, we now expect core net finance expense to be around $64 million, compared to our previous guidance of around $55 million

We will announce our interim results for the six months ended 30 June 2022 on 4 August 2022

 

Contacts

APCO Worldwide

Bedour Mossa

(m) +971 52 905 2468

bmossa@apcoworldwide.com

Iraq Stock Exchange Closes Q1 of the Year at $11.3 billion Mcap

 DUBAI, United Arab Emirates-Friday 29 April 2022 [ AETOS Wire ]

Iraq Stock Exchange (ISX) continued to grow in the first quarter of 2022 by reaching $11.3 billion Mcap, up 8% compared to end of 2021. This inspite of the political instability and weak interest due to lack of information about the market. The banking sector is 45.9% of total Map with 43 listed banks, followed by 41.5% for the telecom sector with two mobile operators, the industry sector at 7.3% share with 20 companies, and various sectors taking up the remainder of the share.

Rabee Securities ISX Index, RSISX Index, which is accepted as a benchmark index in the market, increased by 15.5% in 1Q22, while USD RSISX Index went up by 16.2%. The trading volume of the ISX increased 95% year on year to $112.9 million in 1Q22. ISX has five sessions per week from 10:00 am to 1:00 pm (pre-session: 09:30 – 10:00 am, trading hours: 10:00 – 01:00 pm, cross orders time: 01:00 to 01:30 pm).

Ayşegül Özge Özgür, SVP, Head of Research, said:

"Banking sector played a major role again in trading in the first quarter of 2022 and constituted 70% share in total trading by doubling to $78.7 mn. We expect to see increase in demand on the ISX as the price of oil remains high, the real GDP of Iraq will grow the 6th highest in the world in 2022 according to IMF and the long-awaited government formation will be completed.

In 2021, 15 ISX-listed companies decided to distribute dividend with yields between 0.01% and 12.5% and with an average yield of 4.2%, while in 1Q22 three companies announced dividend distribution decision with yields between 2.9% and 5.2%. We expect to have dividend distribution decisions from other companies in the following months.

Contacts

Mohammed Al Barazenjey 

+971557163727

mb@saharapr.com

Personetics Launches Sustainability Insights, a Next-Generation Solution for Banks to Help Customers Reduce Their Carbon Footprint

 New customer transaction data-driven solution enables banks to show customers their carbon footprint and suggests ways to reduce emissions with greener spending choices and climate-friendly financial goals

NEW YORK & TEL AVIV-Friday 29 April 2022 [ AETOS Wire ]

(BUSINESS WIRE) -- Personetics, the leading global provider of financial data-driven personalization, customer engagement, and advanced money management capabilities for financial institutions, today announces the launch of Sustainability Insights. This new offering, included within the Personetics engagement platform, will help banks meet growing customer demand and regulatory expectations for environmentally responsible banking and sustainable finance. Personetics is partnering with industry-leading impact fintech ecolytiq, whose Sustainability-as-a-Service® solution enhances the data models of Sustainability Insights, making them more precise, personalized, and actionable.

The Personetics Sustainability Insights solution is the world’s first to show banking customers the carbon footprint of every banking transaction and recommend personalized actions to reduce carbon emissions – such as by making purchases from lower-carbon merchants or categories or saving for climate-friendly financial goals. Sustainability Insights are fully embedded into the Personetics financial data-driven engagement platform, based on advanced data analytics of billions of customer transactions.

Beyond just tracking carbon emissions and showing customers their personal carbon footprint, Sustainability Insights is a complete integrated approach that also assesses other factors, such as overall ESG company information to further calculate the individual impact. It also enables banks to recommend their own existing products which may help a customer take more sustainable financial decisions.

Sustainability Insights is based on Personetics’ four pillars of sustainable finance strategy:

Integrated: The Sustainability Insights are fully integrated into the existing financial data-driven engagement platform and accessible within each participating financial institution’s digital channels; customers can now see their carbon footprint and receive recommendations within their bank’s mobile app.

Relatable: Sustainability Insights are based on each customer’s own financial transaction data. People can see the carbon emissions of their everyday spending decisions – and get advice on how to reduce carbon emissions with their financial choices.

Interactive: Sustainability Insights are easy to understand and engaging for banking customers, with an easy-to-use digital banking user experience.

Actionable: Customers can quickly take action to reduce their carbon emissions, such as by opening a savings account to save money for solar panels or an electric vehicle or deciding to purchase a different product or shop at a more climate-friendly store.

Key capabilities of the Sustainability Insights offering include:

Providing a personalized, holistic financial map that visually demonstrates the carbon emissions of customer spending or investments.

Giving customers the ability to take action to reduce their carbon emissions with personalized insights and advice, depending on their financial situation. For example, the solution might suggest alternative merchants that are more carbon friendly, suggest a savings goal for installing solar panels, offer green investment products, or allow a customer to set a carbon target and track their progress through their spending.

Personalization and Engagement: Actively engaging with the user to increase the accuracy of the insights via quizzes and feedback insights.

To provide banking customers with the most precise, and actionable climate impact data, Personetics has integrated ecolytiq's country level models with its own proprietary capabilities. ecolytiq provides financial institutions with country-specific data sources and models to help them achieve best-in-class carbon impact calculations.

For increased depth of data, Personetics’ Sustainability Insights also partners with additional global providers of carbon emission research to offer various merchants footprint or spending categories within specific countries.

Personetics’ Sustainability Insights will empower financial institutions to be leaders in environmentally responsible banking and will help customers take action to choose a more sustainable lifestyle with better-informed financial choices. Data from Deloitte shows 28% of consumers have already stopped purchasing certain brands or products due to sustainable or ethical concerns, and dozens of the world’s banks are already committing to change through the UN’s Principles for Responsible Banking.

Banks will also be able to feed insights from the Personetics platform into their ESG reporting by tracking and measuring the actions customers are taking to reduce their carbon footprint. This can help financial institutions demonstrate significant leadership in supporting their customers while fighting climate change.

David Sosna, CEO of Personetics, said:

“We are excited to launch our new Sustainability Insights, backed by the industry-leading data sources of our partner ecolytiq. Personetics Sustainability Insights are the next evolution of sustainable finance – beyond just showing bank customers their carbon footprint, we offer them specific actions that they can take today to reduce their carbon impact, choose climate-friendly savings goals, and push the industry in a greener direction.

“Sustainability Insights also drive business impact for financial institutions by improving customer engagement, creating new occasions for targeted cross-selling, and recommending specific banking products and new accounts in a way that is personalized for each customer’s financial situation and future goals. This will create deeper relationships with banking customers and ultimately support banks’ ESG reporting. Every financial institution can be a leader in green banking with Sustainability Insights.”

Ulrich Pietsch, CEO, ecolytiq said:

“The financial industry will play a major role in fighting climate change. This starts by providing people with the information they need to make greener decisions. Banks that act now by embracing sustainability will be the first to reap its benefits for years to come. By partnering with Personetics, we’re excited to be able to help even more financial institutions across the world with in-depth data about their customers’ carbon footprint, so they can suggest actions to improve it.”

The new Sustainability Insights offering is now available on the Personetics platform and is ready to be activated by Personetics’ existing global network of 80 financial institutions with a combined reach of 120 million bank customers.

About Personetics:

Personetics is the global leader in financial data-driven personalization, customer engagement, and advanced money management capabilities for financial services. We are creating the future of “Self-Driving Finance,” where banks can proactively act on their customers’ behalf to help improve their financial wellness and achieve financial goals.

Our industry-leading data analytics solutions harness customer financial transaction data to provide day-to-day actionable insights, personalized recommendations, product-based financial advice, and automated financial wellness programs. We offer solutions for mass market consumer banking, SMB banking, wealth management, and credit card issuers.

We drive business impact for financial institutions by improving relevant product targeting for accurate, efficient cross-selling and upselling. We help financial institutions deepen their customer relationships, increase core deposits and customer retention, expand share of wallet, and boost Customer Lifetime Value.

Personetics currently serves over 80 financial institutions spanning 30 global markets, reaching 120 million customers. We are backed by leading venture capital and private equity investors, with offices in New York, London, Tel Aviv, Singapore, Rio de Janeiro, Tokyo, Paris, Madrid, and Sydney. Learn more at personetics.com

About ecolytiq:

The Sustainability-as-a-Service® solution from ecolytiq enables banks, fintech companies and financial service providers to show their customers the individual impact their purchasing behavior is having on the environment in real time. The ecolytiq software calculates personal environmental impacts, such as CO2 values, on the basis of payment transactions and educates consumers on sustainable spending habits through climate insights. Learn more at www.ecolytiq.com

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005128/en/

Contacts

Media inquiries

Toby Earnshaw / Aimee Cashmore

personetics@pancomm.com

Michal Milgalter, Head of Global Marketing

Michal.milgalter@personetics.com

Media contact ecolytiq:

Yuki Hayashi I ecolytiq GmbH I media@ecolytiq.com

phone: +49 30 2201232-80

SEE Launches Digital Packaging Brand prismiq™

 Packaging made brilliant powered by a portfolio of digital solutions

CHARLOTTE, N.C.-Friday 29 April 2022 [ AETOS Wire ]

(BUSINESS WIRE) -- Sealed Air (NYSE: SEE) today announced the introduction of prismiq™ - a digital packaging brand with a portfolio of solutions for design services, digital printing and smart packaging.

 “The future of digital packaging and graphics is here. prismiq™, powered by our state-of-the-art digital printing technology is creating game-changing value for customers, enabling touchless automation both in our facilities and our customers’ operations, and making sustainability for packaging real,” said Ted Doheny, President & CEO of SEE.

Creating Value for Customers Through Digital Packaging

The prismiq™ brand offers three solution categories:

“With your smart phone, prismiq™ will allow you to see inside the package. Through the SEE™ Mark, multiple data signatures can be transmitted to your phone (QR, bar codes, RFID, recycling codes, date and time stamps, etc.) enhancing the human experience,” said Sergio Pupkin, Chief Growth & Strategy Officer at SEE.

Smart Packaging: prismiq™ eliminates waste and excess packaging while enhancing products and customer engagement. SEE’s end-to-end cloud-based platform generates package-specific digital IDs that collect and manage data along the value chain.

Design Services: SEE designs packaging made to be connected for brand owners. Our team of nearly 200 design specialists work with customers around the world to create custom graphics, design new concepts, and conduct performance testing.

Digital Printing: SEE systems can run multiple designs on a single order, print serialized/digitized codes and images that are package-specific, and allow customers to have flexible order quantities as well as faster turnaround times.

SEE’s Bold Approach to Digital Packaging: Powered by Possibility

“prismiq™ offers a one-stop, integrated approach to make packaging brilliant. We are embedding digital printing capabilities within our manufacturing operations, our customers’ operations and bringing packaging to life in consumers’ homes,” said Carrie Giaimo, Executive Director of Smart Packaging and Design at SEE.

SEE has invested approximately $100 million in digital transformation, including its most recent development: the prismiq™ 5540 (the world’s largest, fastest, flexible digital printing system). This system is first of its kind, capable of wide web, high speed, full-color (including metallics and invisible ink) and double-sided digital printing on flexible and shrinkable materials.

About SEE

Sealed Air (NYSE: SEE) is in business to protect, to solve critical packaging challenges, and to make our world better than we find it. Our automated packaging solutions systems help promote a safer, more resilient and less wasteful global food supply chain, enable e-commerce, and protect goods transported worldwide.

Our globally recognized brands include CRYOVAC® brand food packaging, SEALED AIR® brand protective packaging, AUTOBAG® brand automated systems, BUBBLE WRAP® brand packaging, and SEE™ Touchless Automation™ solutions.

SEE’s Operating Model, together with our industry-leading expertise in materials, engineering and technology, create value through more sustainable, automated, and digitally connected packaging solutions.

We are leading the packaging industry in creating a more environmentally, socially, and economically sustainable future and have pledged to design or advance 100% of our packaging materials to be recyclable or reusable by 2025, with a bolder goal to reach net-zero carbon emissions in our global operations by 2040. Our Global Impact Report highlights how we are shaping the future of the packaging industry. We are also committed to a diverse workforce and inclusive culture through our 2025 Diversity, Equity and Inclusion pledge.

SEE generated $5.5 billion in sales in 2021 and has approximately 16,500 employees who serve customers in 114 countries/territories. To learn more, visit sealedair.com.

Website Information

We routinely post important information for investors on our website, sealedair.com, in the Investors section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 concerning our business, consolidated financial condition and results of operations. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as “anticipate,” “believe,” “plan,” “assume,” “could,” “should,” “estimate,” “expect,” “intend,” “potential,” “seek,” “predict,” “may,” “will” and similar references to future periods. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, expectations regarding the results of restructuring and other programs, anticipated levels of capital expenditures and expectations of the effect on our financial condition of claims, litigation, environmental costs, contingent liabilities and governmental and regulatory investigations and proceedings. The following are important factors that we believe could cause actual results to differ materially from those in our forward-looking statements: global economic and political conditions, currency translation and devaluation effects, changes in raw material pricing and availability, competitive conditions, the success of new product offerings, consumer preferences, the effects of animal and food-related health issues, the effects of epidemics or pandemics, including the Coronavirus Disease 2019, negative impacts related to the ongoing conflicts between Russia and Ukraine and related sanctions, export restrictions and other counteractions thereto, changes in energy costs, environmental matters, the success of our restructuring activities, the success of our merger, acquisition and equity investment strategies, the success of our financial growth, profitability, cash generation and manufacturing strategies and our cost reduction and productivity efforts, changes in our credit ratings, the tax benefit associated with the Settlement agreement (as defined in our most recent Annual Report on Form 10-K), regulatory actions and legal matters, and the other information referenced in the “Risk Factors” section appearing in our most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005251/en/

Contacts

Media

Christina Griffin

Christina.griffin@sealedair.com

704.430.5742